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OBJECTIVES:To assess the lifetime incremental cost-effectiveness ratios (ICER) per
quality-adjusted life-year (QALY) gained and multinomial expected value of per-
fect information (mEVPI) of sequential follicular lymphoma (FL) treatment in
Finland. METHODS: The novel cancer treatments included rituximab (R) and ben-
damustine (B). A probabilistic Markov-model was developed to simulate patients’
transitions between first-line progression-free (PF1), PF2, progression and death
states using a second-order Monte Carlo-simulation, one month cycle, and half
cycle correction. All patients received the recommended induction with R-cyclo-
phosphamide-doxorubicin-vincristine-prednisone (RCHOP). For the RCHOP-induc-
tion responders, the sequence was continued without the first-line R-maintenance
treatment (RCHOP) or with it (RCHOPR). PF1 was based on the best fitting paramet-
ric extrapolation (Gompertz; 4-year treatment benefit trunk) of PRIMA (Primary
RItuximab and MAintenance) data. After RCHOPR or RCHOP, eligible patients were
assigned to second-line RCOPR/B or RCOPR/COP based on the PRIMA results, B
indication/labelling and the recent ESMO (European Society for Medical Oncology)
guideline for FL. PF2s (5-year treatment benefit trunk) were based on the paramet-
ric estimate of EORTC20981 and adjustment based on Rummel’s trial. After PF2
(progression), patients received best supportive care (BSC). Age-dependent death
was set equal to the larger of EORTC20981 or Finnish background mortality. Payer
costs were included in 2010 value, and the most affordable public drug costs (2/
2011; wastage included) were used. EQ-5D-based utilities were set 0.78 for PF1/PF2
and 0.62 for progression. 3% annual discounting was used. RESULTS: The ICERs for
RCHOPR-RCOPR/B-BSC, RCHOPR-RCOPR/COP-BSC and RCHOP-RCOPR/B-
BSC were €9575, €9881 and €8812 per QALY gained in comparison to RCHOP-
RCOPR/COP-BSC, respectively. According to the cost-effectiveness acceptability
frontier, 47% of patients with RCHOP-RCOPR/COP-BSC, 46% and 68% of patients
with RCHOPR-RCOPR/B-BSC were cost effective at the ICER-levels of €5,000
(mEVPI €5,047/patient), €15,000 (mEVPI €3,101/patient) and €25,000 (mEVPI €1,564/
patient) per QALY gained, respectively.CONCLUSIONS: First-line R-maintenance is
an efficient and potentially cost-effective start for FL-treatment sequence.
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OBJECTIVES: Sepsis is a syndrome characterised by a systemic inflammatory re-
sponse to infection. Intravenous immunoglobulin (IVIG) has been proposed as an
adjuvant therapy for sepsis. The need for a high quality randomised controlled trial
(RCT) to evaluate the effectiveness of this treatment has been identified in the
literature. The objectives of the current work were to use value of information
analyses (VOI) to establish whether the costs of carrying out an RCT are outweighed
by the potential benefit of the resulting information. METHODS: A decision model
was developed to evaluate the cost-effectiveness of IVIG (in terms of cost per qual-
ity-adjusted life-year) in adults with severe sepsis. A systematic review coupled
with formal modelling selection process was performed to assess evidence on the
relative effectiveness of IVIG. Further reviews were conducted to inform other
relevant model parameters. Decision uncertainty was presented and the value of
information assessed. RESULTS: A large degree of between study heterogeneity in
the existing evidence base over the relative effectiveness of IVIG could be explained
by a measure of study quality and duration of IVIG therapy. When using this model,
the incremental cost-effectiveness ratio of IVIG was estimated to be £20,850 per
QALY (threshold of £20,000 per QALY), and the probability of IVIG being cost effec-
tive was 0.505. No clear clinical rationale for the association between relative ef-
fectiveness and duration of therapy emerged from existing studies. Alternative
models were evaluated for their impact on cost effectiveness and on the need for
further research. The results demonstrate that conclusions are highly sensitive to
the choice of model used for clinical effectiveness. CONCLUSIONS: Although the
analyses suggested potential value from a large multicentre RCT, the uncertainties
around the design of such a study mean that further dose-ranging/finding studies
should conducted prior to funding any future multicentre RCT.
PODIUM SESSION III:
TAKING HETEROGENEITY INTO ACCOUNT BETWEEN PATIENTS AND BETWEEN
STUDIES
HG1
APPLYING FRAILTY MODEL IN LONGITUDINAL SURVIVALS OF CHRONIC
DISEASES
Li Y, Holtzer-Goor K, Uyl-de Groot C, Al M
iMTA, Erasmus University Rotterdam, Rotterdam, The Netherlands
OBJECTIVES: Survival analysis plays an important role in assessing the effective-
ness of medical product/treatments and the risk factors. Particularly, the acceler-
ated failure time (AFT) model provides the hazard/survival functions to the later
health economic decision model to compute the cost-effectiveness. The model
estimations of the usual survival models rely on the maximum likelihood estima-
tion (MLE), which works under the assumption of independence of observations.
However, this assumption is not always satisfied, especially in the chronic/relaps-
ing disease. A patient with a chronic disease may experience recurrent disease
progressions in the life course. When the progression free survivals (PFS) are re-
corded longitudinally, the PFS of different patients can be considered independent.
Nevertheless, owing to sharing some unobserved heterogeneity, PFS of the same
patients tend to associate with each other. This within-patient association can
affect the estimation accuracy, therefore may misinform the decision makers. Par-
ticularly designed for the multivariate survival analysis, the frailty model takes this
issue into account. METHODS: Fist, in a simulation study, we compared the AFT
model and the Frailty model, where 5000 hypothetical patients are assigned to two
treatment arms, and each patient experiences 5 treatment lines. Second, we apply
both the Weibull AFT model and the Weibull-Gamma frailty model to the real life
data, where 254 patients of chronic lymphocytic leukemia(CLL) have been fol-
lowed, and we conduct a hypothesis test on the significance of frailty term.
RESULTS: The simulation study shows that the estimates of the AFT model deviate
far from the true values when the unobserved heterogeneity is large. The real life
study indicates that the AFT model should be replaced by the frailty model due to
the significance of the frailty term. CONCLUSIONS: In modelling survivals for
chronic disease, the frailty models provide more accurate effect estimation than
the conventional survival model.
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OBJECTIVES: Subarachnoid hemorrhage (SAH) is a cerebrovascular disease leading
to severe disability. SAH-patients show heterogeneous profiles of health-related
quality of life (HrQoL). No methodological approaches to characterize the individ-
ual course of HrQoL following SAH have been developed. The objective was to
characterize individual trajectories concerning HrQoL following SAH by using la-
tent growth mixture modeling (LGMM). METHODS: A total of 113 incident patients
with aneurysmal SAH treated in the University of Bonn between January 2004 and
December 2005 were recruited in this longitudinal study. Clinical parameters (Hunt
and Hess scale, Barthel-Index, Rankin Scale, Beck Depression Inventory) and HrQoL
data (EQ-5D) were evaluated at baseline, 6 and 12 months. LGMM was applied to
analyse the heterogeneity in individual courses of HrQoL after SAH. RESULTS: We
identified four subgroups of patients (latent classes) with different patterns of
HrQoL-course. Class 1 had the worst HrQoL-course with a low score of the EQ-5D
index at baseline (0.33) and a non-significant change in scores over time. Patients in
class 3 showed rapid recovery from initially low EQ-5D scores (0.37) during the first
6 months (D0.47). Patients in classes 2 and 4 had 48-57% better initial HrQoL and
similarly high HrQoL scores after 12 months. Patients in class 4 experienced a
temporary reduction of HrQoL by 55%. The following clinical parameters were
identified to characterize differences between classes: severity of SAH (Hunt and
Hess scale), functional outcome, cognitive impairment and post-stroke depression.
Treatment of post-stroke depression in classes 1 and 4 can improve HrQoL mea-
sures by factor 1.3-2.8. CONCLUSIONS: This methodological approach can be ap-
plied for more elaborated understanding of individual differences in long-term
course of HrQoL after SAH. Identification of different patterns of disease course
using LGMM may help to find subgroups of treatment responders and to assist the
development of individual therapy regimes.
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OBJECTIVES: Colorectal cancer (CRC) is the third most commonly-diagnosed can-
cer worldwide with over one million new cases globally each year. Advances in
treatment and survival have been occurring, which is likely to have increased
lifetime costs of managing the disease. We systematically reviewed and critiqued
the cost-of-illness (COI) literature on CRC. METHODS: We searched Medline, EM-
BASE, CRD and the Cochrane library for CRC COI studies published in English,
January 2000- February 2011. Data was abstracted independently by two reviewers
on: setting, patient population, top-down/bottom-up costs, incident/prevalent ap-
proach, payer perspective, time horizon, costs included, cost source and per-per-
son costs. We developed a framework to compare study methodologies and assess
homogeneity/heterogeneity. RESULTS: Twenty-six papers met the inclusion crite-
ria from the US (17), France (3), the UK (2), Canada (2), Switzerland (1) and Taiwan
(1). Extensive methodological heterogeneity existed between studies. 17 studies
employed top-down costings; 6 studies were prevalent, 8 incident and the remain-
der mixed. Time horizons ranged from 1-year post-diagnosis to lifetime. 25 studies
included healthcare payer direct medical costs; 2 included indirect costs; 1 consid-
ered patient costs. The included papers described case-control studies based on
claims/reimbursement data(10), examinations of patient charts (5) and analysis of
claims data(4). There was broad agreement in how studies accounted for time, but
few studies described costs in sufficient detail to allow repeatability. In general
costs were not comparable between studies. There were some commonality in
findings between studies from the same setting and which estimated costs in the
year following diagnosis, but estimates varied greatly for longer time horizons.
CONCLUSIONS: Methodological heterogeneity and lack of transparency made it
almost impossible to compare CRC costs between studies or over time. For COI
studies to be more informative, and amenable to external comparison, researchers,
decision-makers and funders should adopt more standardised methodologies and
promote greater transparency.
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